[go: up one dir, main page]

WO2011063774A3 - Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes - Google Patents

Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes Download PDF

Info

Publication number
WO2011063774A3
WO2011063774A3 PCT/CZ2010/000120 CZ2010000120W WO2011063774A3 WO 2011063774 A3 WO2011063774 A3 WO 2011063774A3 CZ 2010000120 W CZ2010000120 W CZ 2010000120W WO 2011063774 A3 WO2011063774 A3 WO 2011063774A3
Authority
WO
WIPO (PCT)
Prior art keywords
pectin
steroids
pharmaceutical compositions
compositions based
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2010/000120
Other languages
English (en)
Other versions
WO2011063774A2 (fr
Inventor
Vladimir Kral
Zbynek Oktabec
Josef Jampilek
Tomas Pekarek
Bohumil Proksa
Jiri Dohnal
Anna Malovikova
Anna Ebringerova
Anna Rezacova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of WO2011063774A2 publication Critical patent/WO2011063774A2/fr
Publication of WO2011063774A3 publication Critical patent/WO2011063774A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne un procédé permettant de fabriquer une composition pharmaceutique contenant une substance active sous la forme d'un produit d'addition (complexe) avec une pectine, éventuellement dans un mélange contenant un glucane. Le produit d'addition ainsi obtenu se caractérise par une plus grande solubilité dans l'eau par rapport à la substance pharmaceutiquement active d'origine. Le produit d'addition (complexe) constitué de la substance active et de la pectine est ensuite utilisé pour préparer une forme galénique à libération ciblée (libération lente) dans l'intestin.
PCT/CZ2010/000120 2009-11-25 2010-11-25 Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes Ceased WO2011063774A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20090790A CZ302789B6 (cs) 2009-11-25 2009-11-25 Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
CZPV2009-790 2009-11-25

Publications (2)

Publication Number Publication Date
WO2011063774A2 WO2011063774A2 (fr) 2011-06-03
WO2011063774A3 true WO2011063774A3 (fr) 2012-01-19

Family

ID=43743524

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000120 Ceased WO2011063774A2 (fr) 2009-11-25 2010-11-25 Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes
PCT/CZ2010/000121 Ceased WO2011063775A2 (fr) 2009-11-25 2010-11-25 Complexes de sartans à base de pectine et compositions pharmaceutiques fabriquées à partir de ces complexes
PCT/CZ2010/000122 Ceased WO2011063776A2 (fr) 2009-11-25 2010-11-25 Complexes solubles bêta-glucane-api pour utilisation pharmaceutique

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000121 Ceased WO2011063775A2 (fr) 2009-11-25 2010-11-25 Complexes de sartans à base de pectine et compositions pharmaceutiques fabriquées à partir de ces complexes
PCT/CZ2010/000122 Ceased WO2011063776A2 (fr) 2009-11-25 2010-11-25 Complexes solubles bêta-glucane-api pour utilisation pharmaceutique

Country Status (2)

Country Link
CZ (1) CZ302789B6 (fr)
WO (3) WO2011063774A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015026960B1 (pt) 2013-04-27 2021-07-27 The Regents Of The University Of California Métodos para a produção de intermediários reativos a partir de biomassa e para a solubilização e conversão catalítica combinadas de biomassa
CN103622928A (zh) * 2013-11-27 2014-03-12 广西大学 一种果胶基载体材料的制备方法及其应用
US10646495B2 (en) 2017-08-30 2020-05-12 Antares Pharma, Inc. Testosterone ester triglyceride formulations
CN115252587A (zh) * 2022-08-19 2022-11-01 南京泛太化工医药研究所 一种口腔速溶膜及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505966A (en) * 1990-07-04 1996-04-09 Kabi Pharmacia Ab Therapeutical composition and process for its preparation
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US20060188530A1 (en) * 1998-07-24 2006-08-24 Yoo Seo H Bile preparations for gastrointestinal disorders

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950689A (en) 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
CA2014244A1 (fr) * 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Composes d'anthracycline stabilises
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
RO107187B1 (ro) 1992-02-11 1993-10-29 Icn Galenika Sa Compoziție farmaceutica, antiacida, stabilizata și procedeu de obținere
HU213872B (en) * 1993-09-08 1997-11-28 Mta Koezponti Kemiai Kutato In Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds
KR0121127B1 (ko) 1994-05-09 1997-11-13 강박광 이온성 고분자 네트웍을 갖는 피부약물전달체계
DE69615583T2 (de) * 1996-01-16 2002-07-11 Advanced Polymer Systems, Inc. Örtliche arzneistoffabgabe in tieferen magendarmtraktabschnitten
IT1282381B1 (it) 1996-04-29 1998-03-20 Trans Bussan S A Nuove formulazioni di diacereina, ottenute per inclusione del principio attivo in idrogel polisaccaridi
AU3136897A (en) 1996-05-22 1997-12-09 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US6200574B1 (en) 1996-07-08 2001-03-13 Jose A. Diaz Chemical composition for aiding the absorption, binding and elimination of undigested fat
US5891441A (en) 1996-07-08 1999-04-06 Diaz; Jose A. Chemical composition and method for more rapidly aiding the absorption, binding an elimination of undigested fat in the human body
FR2752843B1 (fr) * 1996-08-30 1998-10-16 Sod Conseils Rech Applic Copolymeres reticules a base de polymeres polycarboxyliques et leur utilisation comme support de composition pharmaceutique
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040136961A1 (en) 1997-10-09 2004-07-15 Ales Prokop Nanoparticulate composition for efficient gene transfer
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
JP4754067B2 (ja) 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
KR20000011247A (ko) 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
RU2169002C2 (ru) 1999-04-19 2001-06-20 Пятигорская государственная фармацевтическая академия Способ получения инулин-пектинового концентрата в порошке для медицинских и пищевых целей из высушенного сырья
US20020119928A1 (en) 2000-10-27 2002-08-29 Mcanalley Bill H. Dietary supplement compositions
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US7276250B2 (en) 2001-07-06 2007-10-02 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
EP1423109B1 (fr) 2001-09-03 2005-10-26 DSM IP Assets B.V. Compositions contenant une pectine et de l'acide ascorbique
JP2003127783A (ja) 2001-10-25 2003-05-08 Mitsuboshi Belting Ltd フロアコンソール
DE10212553A1 (de) 2002-03-16 2003-09-25 Knoell Hans Forschung Ev Verwendung einer Formulierung zur in situ Biodegradation von Wundabdeckungen
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
EP1490029A4 (fr) 2002-03-22 2006-02-22 Ranbaxy Lab Ltd Systeme d'administration de medicaments a liberation controlee de pravastatine
DE20205184U1 (de) 2002-03-27 2002-12-19 Bartz, Volker, 35440 Linden Blutfettsenker zur oralen Einnahme
DE10214005A1 (de) 2002-03-27 2003-10-09 Volker Bartz Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente
DE10250083A1 (de) 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
KR100522239B1 (ko) * 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
JP2004059440A (ja) 2002-07-25 2004-02-26 Mikasa Seiyaku Co Ltd 肌荒れ防止および粘膜修復剤
US20040087514A1 (en) 2002-09-06 2004-05-06 Hughes Thomas E Nutritional compositions
JP2004107295A (ja) 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization ヒスタミン遊離抑制剤
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
CZ296475B6 (cs) 2002-12-09 2006-03-15 Mikrobiologický Ústav Av Cr Zpusob fermentacní prípravy extracelulárního glukanu pomocí hub Claviceps sp.
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040241223A1 (en) 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
CN100477999C (zh) 2003-12-29 2009-04-15 湖南华纳大药厂有限公司 胶体果胶铋分散片
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
WO2005084648A1 (fr) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Compositions pharmaceutiques comprenant du candesartan cilexetil
JPWO2005084703A1 (ja) 2004-03-09 2007-11-29 株式会社Ｎｒｌファーマ 徐放性の口腔用組成物
DE102004019916A1 (de) 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
WO2005105040A2 (fr) 2004-04-26 2005-11-10 Micelle Products, Inc. Preparation hydrosoluble de vitamines liposolubles, agents pharmaceutiques et leurs applications
WO2006002106A2 (fr) 2004-06-22 2006-01-05 Pro-Pharmaceuticals, Inc. Compositions et procedes pour la codelivrance de medicaments anticancereux, de medicaments anti-angiogeniques, et d'un polysaccharide
WO2006015627A1 (fr) * 2004-08-13 2006-02-16 Symrise Gmbh & Co. Kg β-(1,3)-β-(1,4)-GLUCAN EN TANT QUE VEHICULE POUR DES SUBSTANCES CHIMIQUES
EP1845948A2 (fr) * 2005-02-09 2007-10-24 DA Volterra Administration au niveau du colon d'agents actifs
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK1883396T3 (da) 2005-05-18 2013-10-07 Centre Nat Rech Scient Afgivelse af adsorptionsmidler til tyktarmen
CN100340295C (zh) 2005-06-29 2007-10-03 山西安特生物制药股份有限公司 一种口服复方胶体果胶铋制剂及制备方法
ES2279695B1 (es) 2005-08-01 2008-08-01 Jesus Antas Pharma, S.A. Nuevas formulaciones solidas de carotenoides y procedimiento para su obtencion.
JP4817042B2 (ja) 2005-08-26 2011-11-16 国立大学法人三重大学 Ａｌを含むＩＩＩ族窒化物結晶の作製方法、およびＡｌを含むＩＩＩ族窒化物結晶
US20070167395A1 (en) 2006-01-17 2007-07-19 Isaac Eliaz Compositions and methods for treating diabetes
KR101234799B1 (ko) * 2006-02-07 2013-02-20 삼성전자주식회사 이동 로봇 제어 장치 및 방법
KR100912680B1 (ko) * 2006-03-16 2009-08-19 (주) 벡스코아 제어 방출 제형
CN101045163B (zh) 2006-03-29 2011-03-30 重庆莱美药业股份有限公司 一种高分子抗癌前药及其制备方法和用途
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
CN100394923C (zh) 2006-05-26 2008-06-18 范晓青 低分子柑桔果胶用于调节血糖血脂和改善脂肪肝中的应用
US20070292480A1 (en) 2006-06-14 2007-12-20 Conopco, Inc., D/B/A Unilever Delivery System for Ingestible Components
EP2063888A4 (fr) * 2006-09-05 2009-11-04 Astrazeneca Ab Composition pharmaceutique comprenant du candesartan cilexetil
CA2678131A1 (fr) 2006-11-17 2008-05-22 Antoine Andremont Distribution colique a l'aide de billes zn/pectine avec un revetement d'eudragit
JP5139515B2 (ja) * 2007-04-25 2013-02-06 テバ ファーマシューティカル インダストリーズ リミティド 医薬賦形剤複合体
EP2172193A1 (fr) * 2008-10-02 2010-04-07 Capsulution Nanoscience AG Compositions de nanoparticules améliorées de composés faiblement solubles
CZ20098A3 (cs) * 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505966A (en) * 1990-07-04 1996-04-09 Kabi Pharmacia Ab Therapeutical composition and process for its preparation
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US20060188530A1 (en) * 1998-07-24 2006-08-24 Yoo Seo H Bile preparations for gastrointestinal disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONALD E. CADWALLADER ET AL: "Effect of macromolecules on aqueous solubility of cholesterol and hormone drugs", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 70, no. 4, 1 April 1981 (1981-04-01), pages 442 - 446, XP055013096, ISSN: 0022-3549, DOI: 10.1002/jps.2600700426 *
GARCIA ROJAS ET AL: "Cholesterol removal in liquid egg yolk using high methoxyl pectins", CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS, LTD. BARKING, GB, vol. 69, no. 1, 30 March 2007 (2007-03-30), pages 72 - 78, XP022009490, ISSN: 0144-8617, DOI: 10.1016/J.CARBPOL.2006.09.004 *

Also Published As

Publication number Publication date
WO2011063774A2 (fr) 2011-06-03
WO2011063775A3 (fr) 2012-01-26
WO2011063775A2 (fr) 2011-06-03
WO2011063776A2 (fr) 2011-06-03
CZ302789B6 (cs) 2011-11-09
WO2011063776A3 (fr) 2012-05-31
CZ2009790A3 (cs) 2011-06-01

Similar Documents

Publication Publication Date Title
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
MX379386B (es) Proceso de glicoconjugación.
WO2012079092A3 (fr) Compositions d'undécanoate de testostérone
NZ599594A (en) Fast dissolving solid dosage form
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
WO2013101897A3 (fr) Compositions et procédés d'administration d'oméprazole plus acide acétylsalicylique améliorés
JP2010535814A5 (fr)
MX2011011871A (es) Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina.
WO2010089361A3 (fr) Procédé de préparation d'une composition pharmaceutique contenant de l'ézétimibe
WO2010097243A3 (fr) Procédé de fabrication de formes posologiques orales de solifénacine et de ses sels pharmaceutiquement acceptables
WO2012106551A1 (fr) Compositions de bakuchiol pour le traitement d'une hyperpigmentation post-inflammatoire
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
WO2015034678A3 (fr) Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
WO2011056775A3 (fr) Compositions de cellulose microcristalline et de phosphate de calcium utiles en tant qu'excipients pharmaceutiques
EP2524687A3 (fr) Composition sous forme de gelée comestible, préparation sous forme de gelée et méthode de production de préparation sous forme de gelée
WO2012073170A3 (fr) Composition galénique adaptée à l'administration à un animal non-humain, utilisations de celle-ci et méthodes associées
WO2011063774A3 (fr) Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes
TW201129386A (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
TN2012000436A1 (en) Agomelatine hydrobromide hydrate and preparation thereof
CN105616178A (zh) 一种花露水
WO2010020799A3 (fr) Composition
GB201309925D0 (en) Preparation method for caspofungin analog
WO2014006635A3 (fr) Compositions orales solides de silodosine
PH12013500980A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
WO2008079963A3 (fr) Compositions pharmaceutiques comprenant des complexes ioniques d'ingrédients pharmaceutiques actifs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810843

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10810843

Country of ref document: EP

Kind code of ref document: A2